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esponsibility of InstAbstract RNAs have diverse structures that include bulges and internal loops able to form tertiary
contacts or serve as ligand binding sites. The recent increase in structural and functional information
related to RNAs has put them in the limelight as a drug target for small molecule therapy. In addition, the
recognition of the marked difference between prokaryotic and eukaryotic rRNA has led to the
development of antibiotics that speciﬁcally target bacterial rRNA, reduce protein translation and thereby
inhibit bacterial growth. To facilitate the development of new antibiotics targeting RNA, we here review
the literature concerning such antibiotics, mRNA, riboswitch and tRNA and the key methodologies used
for their screening.
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Deoxyribonucleic acid (DNA) is the major genetic material in
eukaryotes and generally exists in the form of double-stranded
helices1. In contrast, ribonucleic acid (RNA) can fold into number-
less tertiary structures that reﬂect its diverse functions. Thus it
serves as the genetic material in some viruses, as the mediator
of genetic information from DNA to protein, as the structural
component in many ribonucleoproteins (RNPs) and, in some
cases, as a catalyst2. RNA is usually associated with RNA-
binding proteins (RBPs) which serve to either protect, stabilize
or transport it and regulate its interaction with other molecules3,4.
RNA plays many crucial roles in protein synthesis, transcriptional
regulation and retroviral replication that make it a prime target for
drug action.
The recent publication of high resolution crystal structures of
prokaryotic rRNA subunits has transformed our understanding
of RNA5–8. The structures of RNA alone9,10 and of RNA–protein
complexes11 reveal a variety of tertiary structures and patterns of
RNA–protein interaction. RNA can fold into complex three-
dimensional structures comprising loops, pseudoknots, bulges
and turns which afford speciﬁc binding sites for small molecules12.
Compared to DNA, RNA is not only more ﬂexible but lacks
repair mechanisms which enhance its susceptibility to the action
of therapeutics13. These include both natural and synthetic
compounds that can inﬂuence the biological activity of RNA by
changing its conﬁguration or inhibiting its catalytic function13,14.
Many antibiotics are known to target rRNA in prokaryotes
and thereby alter protein translation15,16. Their diverse struc-
tures (Fig. 1A and B) witness both to the importance attached to
this class of drugs and to the long period of their development
since their discovery in the 1930s. Concomitant with the
marketing of powerful antibiotics has emerged the phenomenon
of antibiotic resistance which poses a serious threat to human
health. The recent slow-down in the pace of novel antibiotic
development17,18 has further complicated the global health
issue. However, antibiotics remain an attractive area for invest-
ment and represent the third largest therapeutic area with global
ﬁnancing of more than $34 billion in 200619. To assist in the
discovery of new antibiotics, we here summarize the most
commonly used drugs targeting bacterial rRNA in clinical
development.2. Antibiotic drugs targeting rRNA
rRNA is the most commonly exploited RNA target for small
molecules. The bacterial ribosome comprises 30S and 50S
ribonucleoprotein subunits, contains a number of binding sites
for known antibiotics and is an attractive target for novel anti-
bacterial agents. The large difference between prokaryotic and
eucaryotic rRNA enables rRNA-targeting against a broad spectrum
of pathogenic bacteria20. Bacterial ribosomes have two ribonu-
cleoprotein subunits of which approximately two-thirds are RNA.
The bacterial rRNA includes 5S, 16S and 23S rRNA, the smallest
(5S rRNA) being a 120 nt RNA. The smaller 30S subunit
contains a single 1500 nt RNA (16S rRNA) and about 20
different proteins while the larger 50S subunit contains a 2900
nt RNA (23S rRNA) and about 30 different proteins21. Recently,
the application of X-ray crystallography has elucidated many
antibiotic-binding sites on the ribosomal subunit22,23 facilitating
the design of novel antibiotics Fig. 2.2.1. Aminoglycoside antibiotics
Aminoglycosides are a group of well-known antibiotics that have
been used successfully for over half a century. Streptomycin and
spectinomycin are typical examples which function by binding to
speciﬁc sites on prokaryotic rRNA and affecting the ﬁdelity of
protein synthesis. The rRNA aminoacyl-tRNA site (rRNA A-site)
is a major target for aminoglycosides which, because of the
difference between prokaryotic 16S and human 18S rRNA,
selectively kills bacterial cells24. Binding of drug to the 16S
subunit near the A-site of the 30S subunit leads to a decrease in
translational accuracy and inhibition of the translocation of the
ribosome23,25–29. Direct binding to 16S rRNA has been demon-
strated by NMR27, mass spectroscopy29, surface plasmon reso-
nance28 and X-ray crystallography23.
The therapeutic and adverse effects of the aminoglycosides
have been intensively studied. The main issue in clinical practice
relates to their toxicity and the rapid increase in the emergence of
resistant strains. Hopefully, modiﬁcation and reconstruction of
sugar moieties will lead to new aminoglycoside derivatives that
will overcome the undesirable properties of the naturally occurring
compounds30. A small library of four aminoglycosides that bind to
a 16384-member bacterial rRNA A-site-like internal loop has been
established to recognize the RNA motifs using two-dimensional
combinatorial screening (2DCS). This may enable the rational and
modular design of small molecules targeting RNA31.
2.1.1. Streptomycin
Streptomycin disturbs several steps of protein synthesis leading to
translational errors and slowdown of translocation32–35. It binds
ﬁrmly to a single site on 16S rRNA36–38 without binding to the
ribonucleoprotein39 as supported by footprinting and mutation
studies. Footprinting studies showed that streptomycin protects
speciﬁc residues of 16S rRNA within the 30S subunit40 and can be
linked to speciﬁc portions of 16S rRNA41. Moreover, a mutation
in Euglena chloroplast 16S rRNA resulted in streptomycin
resistance42 and mutations in different regions of Escherichia coli
16S rRNA changed the ribosomal response to streptomycin43–48.
Streptomycin also interacts with ribosomal proteins in the 30S
subunit49,50 and mutations in S4, S5 and S12 ribosomal proteins
are shown to inﬂuence its binding51.
Streptomycin can bind to E. coli 16S rRNA in the absence of
ribosomal proteins and can protect bases in the decoding center
from dimethyl sulfate (DMS) attack52. These interactions were
evaluated in the classic high ionic strength buffer (20 mmol/L
MgCl2, and 300 mmol/L KCl) used to separate active 30S subunits
from 16S rRNA and ribosomal proteins. A similar set of bases was
protected by streptomycin in RNA fragments corresponding to 16S
rRNA. The magnesium ion is indispensable for the protection of
the decoding analog afforded by streptomycin.
2.1.2. Spectinomycin
Spectinomycin is an aminocyclitol antibiotic produced by Strep-
tomyces spectabilis which inhibits the growth of many Gram-
negative bacteria and is particularly useful in treating gonorrhea.
Chemical footprinting has demonstrated that spectinomycin binds
to the N-7 position of E. coli 16S rRNA40 and the fact that several
mutations in RNA and protein lead to spectinomycin resistance
implicates a probable binding site in 16S rRNA53. Such binding
may block the attachment of elongation factor G and thereby
prevent the translocation of peptidyl-tRNAs from the ribosomal
Figure 1 The structures of antibiotic drugs (streptomycin, spectinomycin, tetracycline, and puromycin) whose mechanism of action is related to
rRNA. A: Streptomycin, spectinomycin and tetracycline target bacterial 16S rRNA; puromycin resembles the 30 end of the aminoacylated tRNA.
B: Lincomycin, clindamycin, and chloramphenicol target bacterial 23S rRNA; mupirocin targets aminoacyl tRNA synthetase.
Weiling Hong et al.260A-site to the P-site. The A(aminoacyl)-site close to the 30-end of
16S rRNA is highly important in the decoding process such that
binding of an aminoglycoside leads to erroneous protein synthesis
and bacterial death. A set of overlapping, complementary 20-O-
methyl (OMe) 10-mer oligoribonucleotides was used to target the
A-site on puriﬁed 30S ribosomal subunits from E. coli and shown
to be almost ideal inhibitors of in vitro translation. However, thecorrelation of inhibition activity with binding strength to the A-site
was limited54.
The X-ray crystallographic structure of the complex between
spectinomycin and the 30S subunit of Thermus thermophilus
conﬁrms that the antibiotic-binding site is in the minor groove
near the end of helix 34 of 16S rRNA23. Spectinomycin can form a
stable complex with multiple RNA bases via hydrogen bonding
Figure 2 A: The secondary structures of partial 16S rRNA (numbers indicate nucleotide positions). Nucleotides interacting with spectinomycin,
tetracycline and streptomycin are marked with red, green and yellow circles, respectively. B: The secondary structures of partial 23S rRNA.
Nucleotides interacting with chloramphenicol, lincomycin and clindamycin, puromycin and tetracycline are marked with purple, green, yellow, and
red circles, respectively.
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for spectinomycin either through homology to helix 34 or by
different ensembles of interactions. It has been shown that over-
expression of 16S rRNA fragments containing helix 34 can induce
some resistance to spectinomycin in vivo55.
2.2. Tetracycline
Tetracycline inhibits binding of RNA to ribosomes56 mainly by inﬂu-
encing binding to the A-site although some reports implicate binding of
Ac-Phe-tRNA to the P-site57,58. A strong binding site exists on the 30S
subunit and a lot of weaker sites on the 30S and 50S subunits59–61.
Tetracycline may incorporate mainly into ribosomal proteins62,63 since,
in the absence of ribonucleoprotein, 16S RNA and the proteins S3, S7,
S8, S14 and S19 show high afﬁnity for tetracycline64 particularly S760.
In addition, using a photoreactive benzophenone derivative of tRNA
[3-(4-benzoylphenyl)propionyl-phenylalanine transfer RNA (BP-Phe-
tRNA)], the photoreaction of 23S RNA was completely inhibited by
tetracycline and tetracycline itself interacted efﬁciently with the loop V
region of 23S RNA65,66. 16S RNA and 23S RNA are targets of
tetracycline and activity data from crosslinked subunits has shown that
tetracycline crosslinks with 16S RNA at the strong binding site67.
2.3. Lincomycin and clindamycin
Lincomycin is a lincosamide antibiotic which, together with its
derivative, clindamycin (7-chloro-7-deoxylincomycin), inhibits bacter-
ial growth by preventing peptide bond formation15,68. The two drugs
act by targeting the peptidyl transferase loop in domain V of 23S
rRNA of the 50S ribosomal subunit which is the site of peptide bond
formation. The peptidyl tranferase loop has a complex tertiary structure
probably containing the adjacent hairpin loop69,70. The fact that a
transition mutation at position 2032 leads to clindamycin resistance in
E. coli and lincomycin resistance in tobacco chloroplast supports this
mechanism of action. The fact that clindamycin is more potent than
lincosamide in inhibiting the growth of Gram negative bacteria is
probably the result of its higher lipid solubility that enables it to more
readily penetrate the bacterial outer membrane and bind at the same
ribosomal target site. In vitro chemical footprinting indicates that the
two antibiotics interact with 23S rRNA in E. coli ribosomes71.
2.4. Chloramphenicol
Chloramphenicol is a broad spectrum antibiotic which acts as a
potent inhibitor of bacterial protein biosynthesis. It has a long
clinical history but bacterial resistance is common. Chloramphe-
nicol footprinting studies with speciﬁc nucleotides has revealed
the binding sites72,73 to be on the 50S ribosomal subunit where
chloramphenicol interacts with the central loop of 23S rRNA
domain V to inhibit peptidyl transferase activity68,71,72. Details of
the binding to the 50S subunits in Deinococcus radiodurans and
Haloarcula marismortui have been revealed by X-ray studies74,75.
Mutations in RNA can affect chloramphenicol binding76,77.3. The possibility of targeting with bacterial messenger RNA
(mRNA)
Some novel drugs to target eukaryotic mRNAs are now being
developed. Although the structure of mRNA is less complicated
than that of rRNA, it still incorporates some special structures suchas hairpins and pseudoknots that provide binding sites for small
molecules. For example, the iron response element (IRE) present
in several mRNAs involved in iron homeostasis78 and identiﬁed in
Alzheimer's amyloid precursor protein is considered to be a target
for small molecules. Another is the non-structured AU-rich
element (ARE) that spatiotemporally regulates mRNA translation
and stability. Some of these interactions are critical for physio-
logical processes and are being explored as targets for drug
discovery78.
Certain mRNAs also use allosteric control to mediate regulatory
responses79–84. For example, the mRNAs encoding enzymes
involved in thiamine (vitamin B1) biosynthesis in E. coli can
bind to thiamine or its pyrophosphate derivative without the need
for protein cofactors85. In addition, bacterial riboswitches that
consist of structured RNA domains usually residing at the 50
untranslated region of mRNAs can directly bind speciﬁc metabo-
lites and serve as logic gates regulating their own expression
without the need for any regulatory proteins. RNA switches may
serve as novel targets for drug discovery since they are widely
used by bacteria to sense changes in cell physiology and to
regulate metabolic pathways. In depth information on this topic is
available in the literature86–88.
Notwithstanding the above, there are big differences between
prokaryotic and eukaryotic mRNAs. These include: (1) the fact
that prokaryotic mRNA does not need to be processed or
transported so that translation by the ribosome can begin imme-
diately after the end of transcription or coupled with transcription.
Splicing of pre-messenger RNA into mature messenger RNA is an
essential step for the expression of most genes in eukaryotes and is
being employed for disease therapy89; (2) the fact that, in general,
the lifespan of prokaryotic mRNA is much shorter than that
of eukaryotic mRNA because the absence of a 50 cap and 30 polyA
in prokaryotic mRNA enables its immediate degradation by
exonuclease.4. Antibiotics relevant to bacterial tRNA
4.1. Puromycin
Puromycin is an aminonucleoside antibiotic derived from
Streptomyces alboniger which causes premature chain termination
during translation in the ribosome. Part of the puromycin molecule
resembles the 30 end of the aminoacylated tRNA90 such that it
enters the A-site and transfers to the growing chain leading to an
immature puromycylated chain and its premature release91. How-
ever, the lack of selectivity of puromycin makes it unsuitable as an
antibiotic and it is now mainly used as a biochemical tool to study
protein synthesis. It is also under investigation as an anticancer
drug92,93.
4.2. Mupirocin
Aminoacyl tRNA synthetase (aaRSs) has been recognized as a
useful drug target and many natural compounds speciﬁcally target
it to inhibit bacterial growth. In fact there are some 20 essential
aaRSs, each of which may represent a potential target for novel
antibiotics. However, mupirocin (pseudomonic acid A) is the only
marketed drug that targets this enzyme. Mupirocin exhibits good
activity against Coagulase-negative Enterococcus faecium,
Haemophilus inﬂuenzae, Moraxella catarrhalis, Staphylococcus
aureus, Streptococcus pyogenes and Streptococcus pneumoniae 94.
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pathogenic fungi such as dermatophytes. Recent genomic and
biochemical research has provided a wealth of information rele-
vant to aaRSs including their crystal structures and active sites.
Clearly they represent promising targets for novel antibiotics95.
Mupirocin inhibits iso-leucyl-tRNA synthetase (IleRS) and
represents the starting point for the development of other aaRS
inhibitors. Pseudomonas ﬂuorescens has a 74-kb gene cluster
encoding mupirocin which includes polyketide synthetase and
a fatty acid synthetase system96,97. Mupirocin is a secondary
metabolite produced during the late stationary phase98 which
inhibits protein synthesis by speciﬁcally binding to bacterial IleRS
and inhibiting the formation of Ile-tRNA. Selectivity studies have
demonstrated that mupirocin inhibits bacterial, archaeal and fungal
IleRS but not their mammalian orthologs99. There are two genes
(ileRS1 and ileRS2) in P. ﬂuorescens which display remarkable
differences100. IleRS2 has no sensitivity to mupirocin and exhibits
eukaryotic features suggesting that, in P. ﬂuorescens, the ileRS2
gene functions to protect the bacteria from mupirocin attack100. A
mutation in E. coli thrS, a Thr-tRNA ligase, can resist an inhibitor
of deacetylase LpxC, one of the most promising targets for the
treatment of multidrug-resistant Gram-negative infections101.
Structural and energetic aspects of the binding of aristololactam-
β-D-glucoside and daunomycin to tRNA(phe) have been investi-
gated using various biophysical techniques102.5. Techniques crucial for the discovery of drugs targeting
RNA
Great strides have been made in the discovery of drugs targeting
RNA. High-resolution NMR, electrospray mass spectroscopy (ESI-
MS), surface plasmon resonance (SPR), together with other tech-
nologies have facilitated discovery in this ﬁeld. For example, the
structure of a 27 nucleotide RNA complexed with an aminoglyco-
side antibiotic has been determined by NMR spectroscopy27; a
technique based on ESI-MS (IBIS Therapeutics) can screen tens of
thousands of compounds in one day29,103 but its high cost limits its
wider application; SPR is a sensitive and convenient technique to
monitor the binding to RNA of up to 100 small molecules per day.
There are also methods to establish the binding situation of
small molecules to RNA in the absence of RNA-binding proteins.
For example, the scintillation proximity assay (SPA) is a means of
screening inhibitors of RNA–protein interaction12. The technique
uses labeled complementary oligonucleotides to monitor the
changes in the equilibrium between the folded and unfolded state
of an RNA stem-loop structure produced by the binding of a small
molecule104. In cells, the interaction between RNA and proteins
can be measured using reporter gene fusion105. Moreover, a novel
method to identify new compounds that disrupt the function of
ribosomes in Mycobacterium tuberculosis106 has identiﬁed two
compounds (T766 and T054) with potent speciﬁc activity against
M. tuberculosis and low toxicity to mice and other bacterial
strains.6. The future of antibiotics targeting bacterial RNAs
The genomic revolution has revealed many RNAs as potential
targets for novel antibiotic drugs. Targeting RNA is challenging
and complementary to traditional drug discovery that focuses
on proteins and may have some advantages. First, more sites areaccessible at the RNA level while targeting proteins is usually
restricted to their active sites. Secondly, it is cost-effective to
subject RNAs to high-throughput screening. With developments in
new drug discovery technologies, targeting RNAs for better
antibiotics is emerging as a new frontier in drug discovery.
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